Healthcare Has Normalized The Abnormal. Raj Panjabi’s New Book Explains Why.

A new book from former Biden official Raj Panjabi unpacks the notion of “normalcy bias.” It may help explain how we have come to accept our country’s underperforming healthcare system.

Dengue Fever Is Rising In Florida—Here’s What Americans Need To Know

Hundreds of cases and one death have been reported in Florida from dengue fever. A doctor breaks down symptoms to watch for and how to prevent it.

AI And Therapeutic Antibody Design

A test of 511 AI-designed antibodies shows AI can improve promising drug candidates, but lab experiments remain essential for discovering safe, developable antibodies.

Medical records giant Epic pauses product development to fix security bugs that risk patients’ data

The health tech software giant, which makes the widely used MyChart system for accessing medical data, will focus on fixing security bugs for the next few weeks.

6 Ways To Protect Your Brain Health Before It Becomes A Memory Problem

A conversation with two leading neurologists share actionable insights on proactive baselining, lifestyle rigor, and sensory health to protect cognitive function.

The ‘Natural’ Supplement Sending People To The ICU

Marketed for over a decade as a natural wellness product, kratom contains mitragynine and its derivative 7-hydroxymitragynine, which both interact with opioid receptors.

The Lesson Of Cornell: When Institutions Protect Themselves, Women Pay

Cornell’s sexual assault allegations echo a case from 41 years ago, exposing how little has changed in who bears the consequences when campus systems fail.

The Cornell Case Raises An Overlooked Health Question

Sexual assault can affect physical and mental health for months or years. Here’s what survivors may face—and what good healthcare should provide.

U.K.’s Pharmacy First Program Sidesteps Larger Problem Of NHS Underfunding

While Pharmacy First could partially relieve wait times at GP offices and emergency rooms, it’s sidestepping the larger chronic problem of NHS underfunding.

Drug Makers React To Most-Favored-Nation And IRA Pricing Policies

The question becomes whether firms will respond by withdrawing drugs from certain markets or delaying launches of their newly approved drugs in these jurisdictions.